Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Stem Cell Opportunity: Taking a Stand when It's Too Early

This article was originally published in Start Up

Executive Summary

The degenerative diseases that are the target of new stem cell therapies represent many of the largest unmet clinical needs in medicine today. According to "Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets in the US, " a report recently published by Medtech Insight, in the future, stem cell therapies will hold a place in numerous markets, each with potential sales in the billions.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts